Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316638 | 0.89 | GRM7 (0.43) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL3317018 | 0.82 | HTR1D (0.52) | MTNR1AMTNR1BCA1CA2PRMT5 | |
| SCHEMBL3316278 | 0.78 | MAOA (0.49) | CA1CA2MAOAMAOBEPHX1 | |
| SCHEMBL459537 | 0.77 | GRIN2B (0.65) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL3318415 | 0.75 | MTNR1A (0.56) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL30612411 | 0.74 | MTNR1A (0.73) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL9851515 | 0.74 | MTNR1A (0.73) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL3320952 | 0.73 | HTT (0.56) | EPHX1 | |
| SCHEMBL3311200 | 0.71 | GRIN2B (0.50) | MTNR1AMTNR1BGRIN2BCA1CA2 | |
| SCHEMBL19280183 | 0.71 | THRB (0.34) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-1933830-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | MTNR1A 42/4885MTNR1B 98/4885GRIN2B 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.